Literature DB >> 8279923

Cardiac allografts from high-risk donors: excellent clinical results.

G Y Ott1, R E Herschberger, R R Ratkovec, D Norman, J D Hosenpud, A Cobanoglu.   

Abstract

Rising waiting list mortality and increasing demand for donor organs have led to extension of traditionally accepted criteria for evaluation of cardiac grafts. From December 1985 to June 1992, 188 cardiac grafts were orthotopically transplanted into 178 recipients. Of these grafts, 38.3% (72/188) were defined as high-risk donors. Risk criteria included prolonged cardiopulmonary resuscitation, age greater than 40 years, high inotrope requirements, undersizing by more than 20% body weight, significant wall motion impairment by echocardiography, elevation of myocardial enzyme levels, and cold ischemia time greater than 4 hours. There were no recipient deaths attributable to primary graft failure in the perioperative period. Operative (30-day), 1-year and 5-year survival was 95.5%, 86.1%, and 77.3%, respectively, in the high-risk group compared with 93.7%, 86.0%, and 67.2%, respectively, in the low-risk donor cohort (p = 0.94). Comparison of duration of postoperative inotrope use, intensive care unit stay, total hospital stay, and in-hospital costs revealed no significant trends favoring either group in postoperative morbidity. Among long-term survivors, development of graft coronary disease was noted in 47.1% (24/51) of the high-risk donor group and only 17.4% (12/69) of the remaining group (p = 0.0005). Left ventricular ejection fractions in the high risk donor group were 0.58 +/- 0.01 at 2 years. Review of this series suggests that selective use of apparently compromised cardiac donors is compatible with excellent cardiac function and survival. Higher incidence of graft vasculopathy may cause significant morbidity during late follow-up.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8279923     DOI: 10.1016/0003-4975(94)90368-9

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  8 in total

1.  Survival benefits of heart and lung transplantation.

Authors:  P Van Trigt; R D Davis; G S Shaeffer; J W Gaynor; K P Landolfo; M B Higginbotham; V Tapson; R M Ungerleider
Journal:  Ann Surg       Date:  1996-05       Impact factor: 12.969

2.  Assessment of Heart Transplant Waitlist Time and Pre- and Post-transplant Failure: A Mixed Methods Approach.

Authors:  Benjamin A Goldstein; Laine Thomas; Jonathan G Zaroff; John Nguyen; Rebecca Menza; Kiran K Khush
Journal:  Epidemiology       Date:  2016-07       Impact factor: 4.822

Review 3.  State of the Art of Combined Heart-Lung Transplantation for Advanced Cardiac and Pulmonary Dysfunction.

Authors:  Jay J Idrees; Gösta B Pettersson
Journal:  Curr Cardiol Rep       Date:  2016-04       Impact factor: 2.931

4.  Bioprosthetic Aortic Valve Replacement in a Donor Heart before Orthotopic Heart Transplantation.

Authors:  Manish Patel; Khashayar K Vahdat; Sriram Nathan; Marija Petrovic; Pranav Loyalka; Biswajit Kar; Igor D Gregoric
Journal:  Tex Heart Inst J       Date:  2017-04-01

Review 5.  Expanding Selection Criteria to Repairable Diseased Hearts to Meet the Demand of Shortage of Donors in Heart Transplantation.

Authors:  John H Yazji; Pankaj Garg; Ishaq Wadiwala; Mohammad Alomari; Emad Alamouti-Fard; Md Walid Akram Hussain; Samuel Jacob
Journal:  Cureus       Date:  2022-05-30

6.  Cardiac transplantation can be safely performed using selected diabetic donors.

Authors:  Sharven Taghavi; Senthil N Jayarajan; Lynn M Wilson; Eugene Komaroff; Jeffrey M Testani; Abeel A Mangi
Journal:  J Thorac Cardiovasc Surg       Date:  2013-03-13       Impact factor: 5.209

7.  Donor predictors of allograft use and recipient outcomes after heart transplantation.

Authors:  Kiran K Khush; Rebecca Menza; John Nguyen; Jonathan G Zaroff; Benjamin A Goldstein
Journal:  Circ Heart Fail       Date:  2013-02-07       Impact factor: 8.790

8.  High-risk heart grafts: effective preservation with Celsior solution.

Authors:  Luca Salvatore De Santo; Cristiano Amarelli; Gianpaolo Romano; Alessandro Della Corte; Ciro Maiello; Bruno Giannolo; Claudio Marra; Marisa De Feo; Michelangelo Scardone; Maurizio Cotrufo
Journal:  Heart Vessels       Date:  2006-03       Impact factor: 2.037

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.